Chia-Hung Chen et al. confirmed that MEK inhibitors can induce AKT activation and drug resistance by inhibiting the negative feedback of ERK-mediated HER2 phosphorylation in breast cancer cell lines [50,51]. Here, ERBB2 is linked to breast carcinoma.